🔎 Search Trends Reveal Immunology Leaders: Rinvoq, Skyrizi & Sotyktu
Discover the latest insights from LucidTrends as we analyze search patterns across the US from 2022 to 2024, uncovering how patient interest is shifting in Immunology treatments. From surging demand for Sotyktu to the steady rise of Skyrizi and Rinvoq, this video breaks down real-world market signals that matter.
📊 Learn how indication-specific searches spike during key approvals, why geographic dominance is tilting in favor of AbbVie, and how the digital mindshare around psoriasis is evolving—plus a look at emerging competitors like Bimzelx and JNJ-2113 (icotrokinra).
Key takeaways include:
✅ Rinvoq and Skyrizi dominate overall interest
✅ Tremfya’s September 2024 UC approval drove a large indication search spike
✅ Sotyktu’s emergence as a central node in treatment-switching interest
✅ Strong association between inflammatory disease treatments and weight management searches
✅ Strategic insights for marketers: from SEO-driven content to cross-therapeutic campaigns
📩 Want to dive deeper into the insights?
➡️ Download the full report here: https://bit.ly/4lwxpR1
➡️ Get in touch with us: info@lqventures.com or at https://www.lqventures.com/
🔔 Don’t forget to like, subscribe, and hit the notification bell to stay updated on the latest healthcare trends & market intelligence!
#Immunology #PsO #PsA #HealthcareTrends #PharmaMarketing #LucidTrends #DigitalHealth #MarketIntelligence #AbbVie #SearchData #PharmaceuticalInsights #Sotyktu #Skyrizi #Rinvoq #UCApproval #PsoriasisSearchTrends